KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling

Leukemia 38(6) 1307-1314

PMID38678093
PMCIDPMC11147755
DOI10.1038/s41375-024-02254-2
发表日期2024-04-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety. In total, 128 of 175 planned patients were randomized to R-HAD + B (n = 64) or R-HAD (n = 64). Median TTF was 12 vs. 2.6 months (p = 0.045, MIPI-adjusted HR 0.69; 95%CI 0.47-1.02). Overall and complete response rates were 63 vs. 45% (p = 0.049) and 42 vs. 19% (p = 0.0062). A significant treatment effect was seen in the subgroup of patients >65 years (aHR 0.48, 0.29-0.79) and without previous ASCT (aHR 0.52, 0.28-0.96). Toxicity was mostly hematological and attributable to the chemotherapeutic backbone. Grade ≥3 leukocytopenia and lymphocytopenia were more common in R-HAD + B without differences in severe infections between both arms. Bortezomib in combination with chemotherapy can be effective in r/r MCL and should be evaluated further as a therapeutic option, especially if therapy with BTK inhibitors is not an option. Trial registration: NCT01449344.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。